The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Open accessAbstract
Background: The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam for treating imipenem-nonsusceptible infections. Methods: Randomized, controlled, double-blind, phase 3 trial. Hospitalized patients with hospital-acquired/ventilator-associated pneumonia, complicated intraabdominal infection, or complicated urinary tract infection caused by imipenem-nonsusceptible (but colistin- and imipenem/relebactam-susceptible) pathogens were randomized 2:1 to 5–21 days imipenem/relebactam or colistin+imipenem. Primary endpoint: favorable overall response (defined by relevant endpoints for each infection type) in the modified microbiologic intent-to-treat (mMITT) population (qualifying baseline pathogen and ≥1 dose study treatment). Secondary endpoints: clinical response, all-cause mortality, and treatment-emergent nephrotoxicity. Safety analyses included patients with ≥1 dose study treatment. Results: Thirty-one patients received imipenem/relebactam and 16 colistin+imipenem. Among mITT patients (n = 21 imipenem/relebactam, n = 10 colistin+imipenem), 29% had Acute Physiology and Chronic Health Evaluation II scores >15, 23% had creatinine clearance <60 mL/min, and 35% were aged ≥65 years. Qualifying baseline pathogens: Pseudomonas aeruginosa (77%), Klebsiella spp. (16%), other Enterobacteriaceae (6%). Favorable overall response was observed in 71% imipenem/relebactam and 70% colistin+imipenem patients (90% confidence interval [CI] for difference, –27.5, 21.4), day 28 favorable clinical response in 71% and 40% (90% CI, 1.3, 51.5), and 28-day mortality in 10% and 30% (90% CI, –46.4, 6.7), respectively. Serious adverse events (AEs) occurred in 10% of imipenem/relebactam and 31% of colistin+imipenem patients, drug-related AEs in 16% and 31% (no drug-related deaths), and treatment-emergent nephrotoxicity in 10% and 56% (P = .002), respectively. Conclusions: Imipenem/relebactam is an efficacious and well-tolerated treatment option for carbapenem-nonsusceptible infections. Clinical Trials Registration: NCT02452047.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Self-citationFreifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
Munoz-Price, L. S., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M., Cornaglia, G., Garau, J., Gniadkowski, M., Hayden, M. K., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70190-7 · Cited by 1,627
Solomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649554 · Cited by 1,558
Tsuji, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., Giacobbe, D. R., Viscoli, C., Giamarellou, H., Karaiskos, I., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2209 · Cited by 949
Self-citationGaronzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., & Nation, R. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01733-10 · Cited by 696
Has antifungal susceptibility testing come of age
Rex, J. H., & Pfaller, M. A. (2002) · Clinical Infectious Diseases · doi:10.1086/342384 · Cited by 361 · cited 1×
“Since in vitro susceptibility can be considered a reasonable predictor of favorable therapeutic response [34], IMI is recommended for treating infections caused by imipenemsusceptible pathogens (including Enterobacteriaceae) [22–24, 35].”
BackgroundZilberberg, M. D., Shorr, A. F., Micek, S. T., Vazquez-Guillamet, C., & Kollef, M. H. (2014) · Critical Care · doi:10.1186/preaccept-6556009101270526 · Cited by 340
Hawkey, P. M., Warren, R. E., Livermore, D. M., McNulty, C. A. M., Enoch, D. A., Otter, J. A., & Wilson, A. P. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky027 · Cited by 334
Cerceo, E., Deitelzweig, S. B., Sherman, B. M., & Amin, A. N. (2016) · Microbial Drug Resistance · doi:10.1089/mdr.2015.0220 · Cited by 313
M100-S11, Performance standards for antimicrobial susceptibility testing
(2001) · Clinical Microbiology Newsletter · doi:10.1016/s0196-4399(01)88009-0 · Cited by 274
Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa
Livermore, D. M., Warner, M., & Mushtaq, S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt178 · Cited by 268
Lucasti, C., Vasile, L., Sandesc, D., Venskutonis, D., McLeroth, P., Lala, M., Rizk, M. L., Brown, M. L., Losada, M. C., Pedley, A., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00633-16 · Cited by 182
Self-citationUpdated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?
Nation, R. L., Garonzik, S. M., Li, J., Thamlikitkul, V., Giamarellos-Bourboulis, E. J., Paterson, D. L., Turnidge, J. D., Forrest, A., & Silveira, F. P. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ964 · Cited by 168
Sims, M., Mariyanovski, V., McLeroth, P., Akers, W., Lee, Y.-C., Brown, M. L., Du, J., Pedley, A., Kartsonis, N. A., & Paschke, A. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx139 · Cited by 166
Self-citationLapuebla, A., Abdallah, M., Olafisoye, O., Cortes, C. D., Urban, C. M., Quale, J. M., & Landman, D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00843-15 · Cited by 147
Papp‐Wallace, K. M., Barnes, M. D., Alsop, J., Taracila, M. A., Bethel, C. R., Becka, S. A., van Duin, D., Kreiswirth, B. N., Kaye, K. S., & Bonomo, R. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00174-18 · Cited by 107
Self-citationChalhoub, H., Sáenz, Y., Rodriguez‐Villalobos, H., Denis, O., Kahl, B. C., Tulkens, P. M., & Françoise Van Bambeke, A. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.09.012 · Cited by 90
Karlowsky, J. A., Lob, S. H., Kazmierczak, K. M., Hawser, S., Magnet, S., Young, K., Motyl, M. R., & Sahm, D. F. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky107 · Cited by 86
Self-citationWu, J., Racine, F., Wismer, M. K., Young, K., Carr, D. M., Xiao, J. C., Katwaru, R., Si, Q., Harradine, P. J., Motyl, M. R., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02323-17 · Cited by 61
Self-citationShortridge, D., Pfaller, M. A., Castanheira, M., & Flamm, R. K. (2017) · Microbial Drug Resistance · doi:10.1089/mdr.2017.0266 · Cited by 53
Cited by
Humphries, R., Bobenchik, A. M., Hindler, J. A., & Schuetz, A. N. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00213-21 · Cited by 1,493
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Paul, M., Carrara, E., Retamar, P., Tängdén, T., Bitterman, R., Bonomo, R. A., de Waele, J., Daikos, G. L., Akova, M., Harbarth, S., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.025 · Cited by 1,056
Bassetti, M., Echols, R., Matsunaga, Y., Ariyasu, M., Doi, Y., Ferrer, R., Lodise, T. P., Naas, T., Niki, Y., Paterson, D. L., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30796-9 · Cited by 828
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Metadata
- Authors
- Motsch, J., Murta de Oliveira, C., Stus, V., Köksal, I., Lyulko, O., Boucher, H. W., Kaye, K. S., File, T. M., Brown, M. L., Khan, I., Du, J., Joeng, H.-K., Tipping, R. W., Aggrey, A., Young, K., Kartsonis, N. A., Butterton, J. R., & Paschke, A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-08-10
- Volume
- 70
- Issue
- 9
- Pages
- 1799-1808
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2968244461
- Cited by
- 422
- References
- 23
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.